BRIEF-Silo Pharma Partners With Allucent To Support Planned FDA Investigational New Drug Application For Spc-15 As A Therapeutic For Ptsd

Reuters11-17

BRIEF-<a href="https://laohu8.com/S/SILO">Silo Pharma</a> Partners With Allucent To Support Planned FDA Investigational New Drug Application For Spc-15 As A Therapeutic For Ptsd

Silo Pharma Inc SILO.O:

SILO PHARMA PARTNERS WITH ALLUCENT TO SUPPORT PLANNED FDA INVESTIGATIONAL NEW DRUG APPLICATION FOR SPC-15 AS A THERAPEUTIC FOR PTSD
SILO PHARMA INC - EXPECTS IND SUBMISSION IN 2026 AND FIH TRIAL POST FDA APPROVAL
SILO PHARMA INC - DATA FROM GLP-COMPLIANT TOXICOLOGY STUDY EXPECTED IN EARLY 2026

Source text: ID:nGNX65fKBQ

Further company coverage: SILO.O

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2584257086?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-17 21:17","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2584257086","market":"nz","top_or_hot":-1,"title":"BRIEF-Silo Pharma Partners With Allucent To Support Planned FDA Investigational New Drug Application For Spc-15 As A Therapeutic For Ptsd","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-<a href=\"https://laohu8.com/S/SILO\">Silo Pharma</a> Partners With Allucent To Support Planned FDA Investigational New Drug Application For Spc-15 As A Therapeutic For Ptsd</title></head><body><p><a href=\"https://laohu8.com/S/SILOD\">Silo Pharma</a> Inc <span>SILO.O</span>:</p><ul><li><p>SILO PHARMA PARTNERS WITH ALLUCENT TO SUPPORT PLANNED FDA INVESTIGATIONAL NEW DRUG APPLICATION FOR SPC-15 AS A THERAPEUTIC FOR PTSD</p></li><li><p>SILO PHARMA INC - EXPECTS IND SUBMISSION IN 2026 AND FIH TRIAL POST FDA APPROVAL</p></li><li><p>SILO PHARMA INC - DATA FROM GLP-COMPLIANT TOXICOLOGY STUDY EXPECTED IN EARLY 2026</p></li></ul><p>Source text: <span>ID:nGNX65fKBQ</span></p><p>Further company coverage: <span>SILO.O</span></p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Silo Pharma Partners With Allucent To Support Planned FDA Investigational New Drug Application For Spc-15 As A Therapeutic For Ptsd</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Silo Pharma Partners With Allucent To Support Planned FDA Investigational New Drug Application For Spc-15 As A Therapeutic For Ptsd\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-17 21:17</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-<a href=\"https://laohu8.com/S/SILO\">Silo Pharma</a> Partners With Allucent To Support Planned FDA Investigational New Drug Application For Spc-15 As A Therapeutic For Ptsd</title></head><body><p><a href=\"https://laohu8.com/S/SILOD\">Silo Pharma</a> Inc <span>SILO.O</span>:</p><ul><li><p>SILO PHARMA PARTNERS WITH ALLUCENT TO SUPPORT PLANNED FDA INVESTIGATIONAL NEW DRUG APPLICATION FOR SPC-15 AS A THERAPEUTIC FOR PTSD</p></li><li><p>SILO PHARMA INC - EXPECTS IND SUBMISSION IN 2026 AND FIH TRIAL POST FDA APPROVAL</p></li><li><p>SILO PHARMA INC - DATA FROM GLP-COMPLIANT TOXICOLOGY STUDY EXPECTED IN EARLY 2026</p></li></ul><p>Source text: <span>ID:nGNX65fKBQ</span></p><p>Further company coverage: <span>SILO.O</span></p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251117:nTUABJPMTF:1","article_id":"2584257086","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2584257086","pubTimestamp":1763385454,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Silo Pharma Partners With Allucent To Support Planned FDA Investigational New Drug Application For Spc-15 As A Therapeutic For PtsdSilo Pharma Inc SILO.O:SILO PHARMA PARTNERS WITH ALLUCENT TO SU","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","BK4202":"服装、服饰与奢侈品","SILO":"SILO PHARMA INC."},"translate_title":"简介-Silo Pharma与Allucent合作，支持Spc-15作为Ptsd治疗药物的FDA新药研究申请","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SILO":0.9},"content_text":"BRIEF-Silo Pharma Partners With Allucent To Support Planned FDA Investigational New Drug Application For Spc-15 As A Therapeutic For PtsdSilo Pharma Inc SILO.O:SILO PHARMA PARTNERS WITH ALLUCENT TO SUPPORT PLANNED FDA INVESTIGATIONAL NEW DRUG APPLICATION FOR SPC-15 AS A THERAPEUTIC FOR PTSDSILO PHARMA INC - EXPECTS IND SUBMISSION IN 2026 AND FIH TRIAL POST FDA APPROVALSILO PHARMA INC - DATA FROM GLP-COMPLIANT TOXICOLOGY STUDY EXPECTED IN EARLY 2026Source text: ID:nGNX65fKBQFurther company coverage: SILO.O","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2584257086","isCrawlerRequest":true}